Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 127
Filter
2.
J Cardiol Cases ; 5(3): e163-e165, 2012 Jun.
Article in English | MEDLINE | ID: mdl-30532930

ABSTRACT

We present a case of a giant fenestration and a fibrous strand rupture of the aortic valve without massive regurgitation. A 56-year-old woman, was referred for coronary revascularization, had II-III degree aortic regurgitation without symptoms of heart failure. On the intraoperative direct view, the non coronary cusp (NCC) had the giant fenestration and the left coronary cusp (LCC) had the fibrous strand rupture. There was no severe inflammation, thrombi, or vegetation. Finally, she had coronary artery bypass surgery and aortic valve replacement. Although fenestration of the aortic valve is not rare, it is hard to determine its configuration preoperatively. When the echocardiographic findings indicate an eccentric regurgitation flow despite the absence of prolapse, we should perform examinations with the possibility of coexisting aortic valve fenestration in mind. Massive regurgitation does not necessarily correspond to a giant fenestration and a fibrous strand rupture. We report a rare case of the unusually large fenestration and the rupture of the fenestrated fibrous strand of the aortic valve without massive regurgitation.

3.
J Cardiol ; 54(1): 134-8, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19632533

ABSTRACT

Incessant ventricular tachycardia and long-standing ectopic beats lead to tachycardia-induced cardiomyopathy. Catheter ablation eliminates ventricular tachycardia and reverses left ventricular (LV) dysfunction. 201-Thallium ((201)Tl) scintigraphy demonstrates perfusion defects with ischemic cardiomyopathy. Reversible perfusion defects are observed even in non-ischemic cardiomyopathy, related to regional flow or metabolism derangements. 123-I-metaiodobezylguanidine ((123)I-MIBG) scintigraphy delineates regional cardiac sympathetic denervation and heterogeneity. We demonstrated the progression of tachycardia-induced cardiomyopathy in a patient with idiopathic LV outflow tract tachycardia using (201)Tl and (123)I-MIBG scintigraphic findings. Regional defects were reversed predominantly in the basal interventricular septal wall in (201)Tl scintigraphy and (123)I-MIBG scintigraphic findings. This report suggests that incessant ventricular tachycardia or long-standing ventricular ectopic beats may develop adverse myocardial remodeling and sympathetic neurological remodeling. Treatment with catheter ablation for tachycardia-induced cardiomyopathy can reverse sympathetic neurological remodeling as well as myocardial structural remodeling.


Subject(s)
Cardiomyopathies/physiopathology , Cardiomyopathies/therapy , Catheter Ablation , Sympathetic Nervous System/physiology , Tachycardia/complications , Ventricular Remodeling/physiology , Aged, 80 and over , Cardiac Complexes, Premature/complications , Cardiomyopathies/diagnostic imaging , Cardiomyopathies/etiology , Humans , Iodine Radioisotopes , Male , Radionuclide Imaging , Radiopharmaceuticals , Tachycardia/therapy , Thallium Radioisotopes
4.
Circ J ; 73(1): 145-51, 2009 Jan.
Article in English | MEDLINE | ID: mdl-19023152

ABSTRACT

BACKGROUND: The efficacy and safety of abciximab were investigated in Japanese patients undergoing percutaneous coronary intervention (PCI) for acute myocardial infarction (MI) or unstable angina. METHODS AND RESULTS: The 973 patients were randomized into 3 groups: the low-dose group (L group) received bolus injection of 0.20 mg/kg followed by 12-h infusion; the high-dose group (H group) received bolus injection of 0.25 mg/kg followed by 12-h infusion; the placebo group (P group) received bolus and infusion of placebo. The incidence of the primary endpoint (30-day post-PCI coronary events: death, MI or urgent revascularization) was 3.6%, 1.6%, and 4.1% in the P, L, and H groups, respectively, with no significant difference between the P and L groups (P=0.104) or between the P and H groups (P=0.772). The incidence of bleeding tended to increase in a dose-dependent manner. CONCLUSION: No significant difference in the incidence of coronary events was found between the placebo and abciximab groups, so the efficacy of abciximab in preventing post-PCI coronary events in Japanese patients was not confirmed.


Subject(s)
Angina, Unstable/therapy , Angioplasty, Balloon, Coronary/methods , Antibodies, Monoclonal/therapeutic use , Anticoagulants/therapeutic use , Immunoglobulin Fab Fragments/therapeutic use , Myocardial Infarction/therapy , Abciximab , Adult , Aged , Aged, 80 and over , Antibodies, Monoclonal/adverse effects , Anticoagulants/adverse effects , Dose-Response Relationship, Drug , Double-Blind Method , Female , Follow-Up Studies , Hemorrhage/epidemiology , Humans , Immunoglobulin Fab Fragments/adverse effects , Japan , Kaplan-Meier Estimate , Male , Middle Aged , Risk Factors
5.
JACC Cardiovasc Interv ; 1(5): 469-79, 2008 Oct.
Article in English | MEDLINE | ID: mdl-19463347

ABSTRACT

OBJECTIVES: This study sought to determine whether initial medical therapy (MT) only or percutaneous coronary intervention plus medical therapy (PCI+MT) is better for patients with low-risk stable coronary artery disease (CAD) indicated for intervention in Japan. BACKGROUND: Several multicenter studies have suggested that in the above patients, an initial management strategy of PCI+MT does not reduce the long-term risk of cardiovascular events more effectively than initial MT only. METHODS: We conducted a randomized comparative study (JSAP [Japanese Stable Angina Pectoris] study) in the previously mentioned patients. RESULTS: The patients were randomized to PCI+MT (n = 192) or initial MT only group (n = 192), and the patient characteristics were very similar in the 2 groups. During the 3.3-year follow-up, there was no significant difference in the cumulative death rate between PCI+MT (2.9%) and MT (3.9%). However, the cumulative risk of death plus acute coronary syndrome was significantly smaller in PCI+MT. CONCLUSIONS: In stable low-risk CAD, PCI+MT may improve long-term prognosis more effectively than MT.


Subject(s)
Acute Coronary Syndrome/prevention & control , Angioplasty, Balloon, Coronary , Cardiovascular Agents/therapeutic use , Coronary Artery Disease/therapy , Acute Coronary Syndrome/etiology , Acute Coronary Syndrome/mortality , Adult , Aged , Angina Pectoris/etiology , Angina Pectoris/prevention & control , Angioplasty, Balloon, Coronary/adverse effects , Combined Modality Therapy , Coronary Artery Disease/complications , Coronary Artery Disease/drug therapy , Coronary Artery Disease/mortality , Female , Humans , Incidence , Japan , Kaplan-Meier Estimate , Male , Middle Aged , Proportional Hazards Models , Risk Assessment , Severity of Illness Index , Time Factors , Treatment Outcome
7.
J Clin Apher ; 22(5): 287-91, 2007.
Article in English | MEDLINE | ID: mdl-17610290

ABSTRACT

We have recognized marked effectiveness for intermittent claudication with low-density lipoprotein (LDL) apheresis in two cases of arteriosclerosis obliterans (ASO). The Case 1 was a 73-year-old man with intermittent claudication of both lower extremities (Fontaine class II), digital subtraction angiography (DSA) revealed complete obstruction of the left common iliac artery, formation of a collateral to the peripheral portion of the left common iliac artery, and diffuse stenosis of the peripheral portion of the right common iliac artery. Ten sessions of LDL apheresis (LDL-A) improved the walking distance from 100 m before to 600 m after LDL-A treatment. The Case 2 was a 61-year-old man with intermittent claudication of the left lower extremity (walking distance: 200 m) began at 59 years. DSA revealed diffuse stenosis of the peripheral portion of the left popliteal artery. Ten sessions of LDL-A improved the walking distance from 200 m before to 800 m after LDL-A. At one month after the end of LDL-A treatment, DSA revealed formation of collateral to the peripheral portion of the left popliteal artery. Our findings suggest that LDL-A combined with drug treatment is safe and useful for the treatment of ASO, especially walking distance improved with short term treatment.


Subject(s)
Arteriosclerosis Obliterans/therapy , Blood Component Removal , Intermittent Claudication/therapy , Lipoproteins, LDL/blood , Aged , Arteriosclerosis Obliterans/blood , Humans , Intermittent Claudication/blood , Lower Extremity/blood supply , Lower Extremity/diagnostic imaging , Male , Middle Aged , Radiography , Treatment Outcome
8.
Clin Exp Hypertens ; 29(3): 165-73, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17497343

ABSTRACT

Basic autonomic nervous function was evaluated in patients with neurocardiogenic syncope (NCS). Atropine, isoproterenol, propranolol, phenylephrine, and phentolamine were administered successively, and parasympathetic nerve activity and beta- (and alpha-) activity, sensitivity, and secretion of the sympathetic nerve were determined in patients with NCS and control subjects. In patients with NCS, beta- and alpha- sensitivity were higher and beta-activity and beta- and alpha-secretion lower than in control subjects. In patients with NCS, the increased basic beta-sensitivity may contribute to induce strong cardiac contractions and augment ventricular mechanoreceptor response, and a compensatory state against diminished neuronal sympathetic activity is suggested by the increased alpha-sensitivity.


Subject(s)
Parasympathetic Nervous System/physiopathology , Sympathetic Nervous System/physiopathology , Syncope, Vasovagal/physiopathology , Adolescent , Adrenergic alpha-Agonists/administration & dosage , Adrenergic alpha-Antagonists/administration & dosage , Adrenergic beta-Agonists/administration & dosage , Adrenergic beta-Antagonists/administration & dosage , Adult , Atropine/administration & dosage , Blood Pressure/drug effects , Blood Pressure/physiology , Female , Heart Rate/drug effects , Heart Rate/physiology , Humans , Infusions, Intravenous , Isoproterenol/administration & dosage , Male , Middle Aged , Parasympathetic Nervous System/drug effects , Parasympatholytics/administration & dosage , Phentolamine/administration & dosage , Phenylephrine/administration & dosage , Propranolol/administration & dosage , Severity of Illness Index , Sympathetic Nervous System/drug effects , Syncope, Vasovagal/blood , Syncope, Vasovagal/diagnosis
9.
Hypertens Res ; 30(1): 39-47, 2007 Jan.
Article in English | MEDLINE | ID: mdl-17460370

ABSTRACT

In hypertensive patients with chronic renal disease, angiotensin receptor blockers (ARBs) are among the first-line drugs, and calcium channel blockers (CCBs) are recommended as a second line. We examined the effects of two therapeutic strategies using ARBs and benidipine, a CCB, on blood pressure (BP), urinary albumin excretion (UAE), and cost-effectiveness in hypertensive patients with albuminuria. Patients whose BP was 140/90 mmHg or higher despite treatment with low- or medium-dose ARBs were assigned randomly to two groups. In Group A (n=14), the ARB dose was maximized and then benidipine was added until BP targets were reached (<130/85 mmHg). In Group B (n=18), benidipine was administered first and then the ARB dose was increased until BP targets were reached. The BP targets were achieved by ARB alone in 36% of Group A patients and by the addition of benidipine in 83% of Group B patients. Finally, BP decreased in each group, reaching the targets in 93% of Group A patients and 94% of Group B patients after a 4-month therapeutic period. UAE was decreased in both groups after a 4-month therapeutic period compared to the allocation period (-33+/-6% in Group A, -31+/-6% in Group B; p<0.001, respectively). The monthly drug cost was higher (11,426+/-880 vs. 8,955+/-410 yen, p=0.012) and the cost-effectiveness of antihypertensive treatment was lower (p=0.003) in Group A than in Group B. We conclude that the addition of benidipine to low- or medium-dose ARB is, in light of the renal protection and the cost-effectiveness of this approach, a useful therapeutic strategy for controlling BP in hypertensive patients with albuminuria.


Subject(s)
Albuminuria/drug therapy , Angiotensin II Type 1 Receptor Blockers/administration & dosage , Dihydropyridines/economics , Hypertension/complications , Hypertension/drug therapy , Kidney/drug effects , Aged , Albuminuria/etiology , Albuminuria/physiopathology , Angiotensin II Type 1 Receptor Blockers/therapeutic use , Blood Pressure/drug effects , Calcium Channel Blockers/economics , Calcium Channel Blockers/therapeutic use , Cost-Benefit Analysis , Dihydropyridines/therapeutic use , Dose-Response Relationship, Drug , Female , Humans , Hypertension/physiopathology , Male , Middle Aged
10.
Circ J ; 71(3): 370-6, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17322638

ABSTRACT

BACKGROUND: Two randomized studies have shown a neurological benefit of therapeutic hypothermia in comatose survivors after out-of-hospital cardiac arrest, but there are no studies of the cardiac neurohormone of B-type natriuretic peptide (BNP) in patients treated with hypothermia. METHODS AND RESULTS: A prospective study was conducted of 109 comatose patients who were treated with mild hypothermia after out-of-hospital sudden cardiac arrest due to cardiac causes and whose BNP level was measured on arrival at the emergency room. The primary endpoint was a favorable neurological outcome at the time of hospital discharge. A total of 45 of the 109 patients had a favorable neurological outcome. The unadjusted rate of a favorable neurological outcome decreased in a stepwise fashion among patients in increasing quartiles of BNP level (p<0.001) and this association remained significant in subgroups of patients. The BNP cutoff value of 80 pg/ml for a favorable neurological outcome had an accuracy of 87.2%. In the multiple logistic-regression analysis, a BNP level of 80 pg/ml or less was an independent predictor of favorable neurological outcome. CONCLUSIONS: The measurement of BNP was found to provide valuable information regarding the neurological outcome of comatose survivors treated with mild hypothermia after out-of-hospital cardiac arrest due to cardiac causes.


Subject(s)
Coma/therapy , Heart Arrest/therapy , Hypothermia, Induced , Natriuretic Peptide, Brain/blood , Predictive Value of Tests , Resuscitation , Aged , Coma/complications , Coma/etiology , Female , Heart Arrest/complications , Heart Arrest/diagnosis , Heart Arrest/etiology , Heart Diseases/complications , Humans , Male , Middle Aged , Nervous System Diseases/diagnosis , Nervous System Diseases/etiology , Prospective Studies , Survivors , Treatment Outcome
11.
Circ J ; 71(2): 180-5, 2007 Feb.
Article in English | MEDLINE | ID: mdl-17251663

ABSTRACT

BACKGROUND: Progress in reperfusion therapy for acute myocardial infarction (AMI) has greatly reduced acute phase mortality, but few data exist regarding the time trends in left ventricular (LV) remodeling in hospital survivors of AMI. METHODS AND RESULTS: The study enrolled 813 patients with AMI who had received reperfusion therapy and survived to hospital discharge. The patients were divided into chronological groups: first treatment received between 1989 and 1992, n=196; 1993 and 1995, n=193; 1996 and 1998, n=211; and 1999 and 2002, n=213. A comparison was made of LV ejection fraction (LVEF) and LV end-diastolic volume index (LVEDVI) at 6 months after symptom onset. Along with the temporal improvements reperfusion therapy, LVEF and LVEDVI improved over time (55+/-14, 58+/-13, 59+/-13, 61+/-13%, p<0.001; 98+/-30, 94+/-27, 90+/-31, 76+/-27 ml/m2, p<0.0001). Multiregression analysis revealed that shortening of the door-to-Thrombolysis In Myocardial Infarction (TIMI)-3 time (time interval from arrival at the emergency room until patients achieved TIMI-3 flow) and achieving substantial TIMI-3 flow were independent predictors for LV remodeling. CONCLUSION: Although this was a retrospective analysis, the results demonstrated that the change in reperfusion therapy aiming at complete reperfusion at an earlier stage after AMI onset has contributed to improving post-MI remodeling.


Subject(s)
Myocardial Infarction/physiopathology , Myocardial Infarction/therapy , Myocardial Reperfusion/methods , Ventricular Function, Left/physiology , Ventricular Remodeling/physiology , Acute Disease , Aged , Disease-Free Survival , Female , Humans , Male , Middle Aged , Myocardial Infarction/diagnosis , Prognosis , Prospective Studies , Regression Analysis , Retrospective Studies , Stroke Volume/physiology , Thrombosis/diagnosis , Thrombosis/physiopathology , Thrombosis/therapy
12.
Heart Vessels ; 21(4): 236-41, 2006 Jul.
Article in English | MEDLINE | ID: mdl-16865299

ABSTRACT

The increasing elderly population will influence the treatment policies adopted in cases of acute myocardial infarction. Considering reperfusion therapy in elderly patients with acute myocardial infarction, we compared three strategies, as follows: primary percutaneous coronary intervention (primary PCI: n = 26), facilitated PCI with half the standard dose of mutant tissue-type plasminogen activator (t-PA) (half + PCI: n = 24), and facilitated PCI with a standard dose of mutant t-PA (standard + PCI: n = 15) between patients 75 and 80 years of age. The rate of acquisition of thrombolysis in myocardial infarction (TIMI-3) flow on initial coronary arteriography was significantly lower in the primary PCI group than in the other two groups (7.7% in the primary PCI group vs 60% in the half + PCI and 66.7% in the standard + PCI group). The incidence of hemorrhagic complications including blood transfusion was not significantly different between primary PCI and facilitated PCI. Considering reperfusion therapy in elderly patients with acute myocardial infarction, we concluded that facilitated PCI may be effective in elderly patients aged 75-80 years.


Subject(s)
Angioplasty, Balloon, Coronary , Myocardial Infarction/surgery , Myocardial Reperfusion/methods , Aged , Aged, 80 and over , Combined Modality Therapy , Female , Humans , Male , Myocardial Infarction/drug therapy , Thrombolytic Therapy , Tissue Plasminogen Activator/therapeutic use
13.
Nihon Rinsho ; 64(4): 771-8, 2006 Apr.
Article in Japanese | MEDLINE | ID: mdl-16613197

ABSTRACT

The proportion of cardiac etiology is more than 50% of the patients of out-of-hospital cardiac arrest and the cause of cardiac etiology is acute coronary syndromes (ACS) in about 70%. Although the mortality rate of acute myocardial infarction with ST elevation was about 7% in the cardiac reperfusion era, there is a high mortality rate in the patients with ACS who developed out-of-hospital cardiac arrest. We summarized the emergency medical service system in Japan and its problems. Achieving the optimal survival rate for out-of-hospital cardiac arrest due to ACS is the challenge now and in the future.


Subject(s)
Angina, Unstable/mortality , Cardiopulmonary Resuscitation , Emergency Medical Services , Heart Arrest/mortality , Myocardial Infarction/mortality , Angina, Unstable/complications , Angina, Unstable/therapy , Heart Arrest/etiology , Heart Arrest/therapy , Humans , Japan/epidemiology , Myocardial Infarction/complications , Myocardial Infarction/therapy , Survival Rate , Syndrome
14.
Int Heart J ; 47(1): 29-35, 2006 Jan.
Article in English | MEDLINE | ID: mdl-16479038

ABSTRACT

The outcome for facilitated percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) is known to be more favorable in cases in which TIMI-3 flow is obtained before PCI. We investigated factors that affect the acquisition of TIMI-3 flow before PCI. Facilitated PCI was performed on 178 patients divided into two groups, a group in which TIMI-3 flow was acquired before conducting PCI and another in which it was not, and their background factors and short-term outcomes were investigated. The hemoglobin concentrations, white blood cell (WBC) counts, and HbA1c values were significantly lower in the group in which TIMI-3 flow was acquired before PCI and significantly more had a history of past smoking. According to the results of logistic analysis, WBC count (odds ratio [OR], 0.865, P = 0.0077), hemoglobin concentration (OR, 0.77, P = 0.0257), and smoking history (OR, 0.266, P = 0.0021) were independent factors that predicted acquisition of TIMI-3 flow. The WBC count and hemoglobin value on arrival at the emergency room and history of smoking were shown to be independent factors for acquisition of TIMI-3 flow before PCI in facilitated PCI.


Subject(s)
Angioplasty, Balloon, Coronary , Coronary Circulation/drug effects , Fibrinolytic Agents/therapeutic use , Myocardial Infarction/therapy , Aged , Aged, 80 and over , Female , Glycated Hemoglobin/analysis , Hemoglobins/analysis , Humans , Leukocyte Count , Male , Middle Aged , Predictive Value of Tests , Smoking
15.
Int Heart J ; 47(1): 131-7, 2006 Jan.
Article in English | MEDLINE | ID: mdl-16479048

ABSTRACT

The case of a 30-year-old man with myocardial infarction localized in the interventricular septum is described. Coronary angiography performed on day 28 after the onset of symptoms revealed ectasia in the right and left coronary arteries, but no overt stenotic or occlusive lesions were present. Spasm was induced in the first septal branch of the left anterior descending artery by an acetylcholine provocation test, and single photon emission computed tomography myocardial perfusion imaging showed a reduced thallium-201 uptake localized in the interventricular septum.


Subject(s)
Coronary Artery Disease/diagnosis , Myocardial Infarction/diagnosis , Adult , Coronary Angiography , Coronary Artery Disease/complications , Coronary Vasospasm/complications , Dilatation, Pathologic , Electrocardiography , Heart Conduction System , Humans , Male , Myocardial Infarction/etiology , Tomography, Emission-Computed, Single-Photon , Ventricular Septum
16.
Circ J ; 69(12): 1514-20, 2005 Dec.
Article in English | MEDLINE | ID: mdl-16308501

ABSTRACT

BACKGROUND: The purpose of this study was to determine whether the extent of atrial electrical remodeling affects the recurrence of atrial fibrillation (AF) after cardioversion of persistent AF (PAF). METHODS AND RESULTS: Internal atrial cardioversion was performed in 47 patients with PAF. The right atrial monophasic action potential duration (RA-MAPD) at pacing cycle lengths (PCLs) of 800-300 ms and P wave signal-averaged electrocardiogram were recorded after cardioversion. Bepridil (150-200 mg/day) and carvedilol (10 mg/day) were administered to all patients after cardioversion. Of the 47 patients, 20 had recurrent AF within 3 months. No relation was observed between age, left atrial dimension, left ventricular ejection fraction, and AF recurrence. The AF duration was significantly longer (p<0.05) and RA-MAPD at PCLs of 800 to 300 ms were significantly shorter (p<0.05) in patients with AF recurrence than in those without recurrence. The mean slope of the RA-MAPD for PCLs between 600 and 300 ms did not differ between the patients with and without AF recurrence. The filtered P-wave duration (FPD) was significantly longer in the patients with AF recurrence than in those without (p<0.05). Multivariate analysis also showed that the RA-MAPD at a PCL of 300 ms and FPD were predictors of AF recurrence (RAMAPD: p=0.038; FPD: p=0.052). CONCLUSION: These results suggest that electrical remodeling related to the repolarization and depolarization may be the main contributors to early AF recurrence after cardioversion under the administration of bepridil and carvedilol.


Subject(s)
Action Potentials , Atrial Fibrillation/diagnosis , Atrial Fibrillation/therapy , Electric Countershock , Aged , Atrial Fibrillation/drug therapy , Bepridil/administration & dosage , Carbazoles/administration & dosage , Carvedilol , Electrocardiography , Electrophysiology , Female , Heart Atria/physiopathology , Humans , Male , Middle Aged , Multivariate Analysis , Predictive Value of Tests , Prognosis , Propanolamines/administration & dosage , Recurrence , Risk Factors
17.
Circ J ; 69(11): 1401-4, 2005 Nov.
Article in English | MEDLINE | ID: mdl-16247218

ABSTRACT

BACKGROUND: The role of arginine vasopressin (AVP) in the heart has yet to be determined. The present study was designed to examine whether AVP is regulated in the human heart. METHODS AND RESULTS: The subjects were 93 patients who underwent coronary angiography and left ventriculography. Blood samples were collected at the aortic root (AO) and the coronary sinus (CS) to measure the plasma levels of AVP. The patients who showed increases in AVP levels at the CS and AO were assigned to the increased AVP group and those who showed no change or a decrease were assigned to the non-increased AVP group. Cardiac function was compared between these 2 groups. There was a significant difference (p<0.0234) in left ventricular end-diastolic volume index between the increased AVP group (125.5 +/-53.4 ml/m2) and the non-increased AVP group (102.2+/-30.6 ml/m2). There was also a significant difference (p<0.0137) in left ventricular stroke volume index between the increased AVP group (66.6+/-23.2 ml/m2) and the non-increased AVP group (54.4+/-18.6 ml/m2). CONCLUSION: These results suggest that both the production of AVP and synthesis with its receptors may be enhanced at regional sites of the human heart in the volume load.


Subject(s)
Arginine Vasopressin/blood , Myocardial Infarction/blood , Myocardium/metabolism , Stroke Volume , Aged , Coronary Angiography/methods , Female , Humans , Male , Middle Aged , Myocardial Infarction/diagnostic imaging , Myocardial Infarction/drug therapy
18.
Am J Cardiol ; 96(8): 1089-94, 2005 Oct 15.
Article in English | MEDLINE | ID: mdl-16214443

ABSTRACT

We hypothesized that a reduction in atherogenic malondialdehyde-modified low-density lipoprotein (MDA-LDL) levels, which may antagonize the action of atheroprotective high-density lipoprotein cholesterol, leads to coronary plaque regression. This study investigated the effects of pravastatin on the serum levels of MDA-LDL and coronary atherosclerosis. In a 6-month prospective study, 75 patients with stable coronary artery disease were randomly assigned to a pravastatin-treatment group (n = 52) or a control group (n = 23). Volumetric analyses were performed in matched coronary artery segments by 3-dimensional intravascular ultrasound. Pravastatin therapy for 6 months resulted in a decrease in coronary plaque volume (14.4%, p <0.0001) and a corresponding reduction in serum MDA-LDL levels (12.7%, p = 0.0001). In the pravastatin treatment group, the percentage of change in plaque volume correlated with changes in the MDA-LDL and high-density lipoprotein cholesterol levels (r = 0.52 and -0.55, respectively, p <0.0001) but not with the changes in any other lipid levels. Multivariate regression analysis revealed that a reduced MDA-LDL level is an independent predictor of plaque regression, as was an increase in high-density lipoprotein cholesterol. In conclusion, these results suggest that the reduction in the MDA-LDL levels induced by pravastatin may serve as a novel marker of coronary atherosclerosis regression.


Subject(s)
Anticholesteremic Agents/therapeutic use , Coronary Disease/drug therapy , Lipoproteins, LDL/blood , Malondialdehyde/analogs & derivatives , Pravastatin/therapeutic use , Cholesterol/blood , Coronary Disease/blood , Coronary Disease/diagnostic imaging , Diabetes Mellitus , Female , Humans , Hypertension/complications , Male , Malondialdehyde/blood , Middle Aged , Risk Factors , Smoking/adverse effects , Ultrasonography
19.
Hypertens Res ; 28(1): 79-87, 2005 Jan.
Article in English | MEDLINE | ID: mdl-15969258

ABSTRACT

To confirm that alpha1, beta adrenoceptor antagonists and angiotensin II type 1 receptor blockers (ARBs) have different abilities to attenuate progressive cardiac hypertrophy despite their comparable lowering of blood pressure, we compared the effect of these agents alone or in combination on hypertensive cardiac hypertrophy. Eight-week-old spontaneously hypertensive rats (SHR) were divided into 7 groups. Single administration of doxazosin, atenolol, or losartan, or half-dose combinations of these drugs were given orally for 6 weeks. The control group did not receive any drugs. The heart weight-to-body weight ratio (HW/BW), left ventricular mass index (LVMI), plasma brain natriuretic peptide (BNP) and left ventricular BNP mRNA expression were measured after 6-week administration. Blood pressure did not differ among the drug-treated groups, all of which showed lower blood pressure than the control group. The HW/BW and LVMI of the drug-treated groups, except the doxazosin group, were lower than in the control group. Moreover, the LVMI values of the groups receiving losartan were significantly lower than those in the groups without losartan (p < 0.05). Plasma BNP of the drug-treated groups was lower than that in the control group (p < 0.05). The left ventricular BNP mRNA expression of the drug-treated groups, except the doxazosin group, was lower than that in the control group. The atenolol group showed a higher level of BNP mRNA than the groups receiving losartan monotherapy or combination therapies (p < 0.05). In conclusion, the ARB had the strongest attenuating effect on the development of hypertensive cardiac hypertrophy, and the alpha1 and beta adrenergic receptor blockers were more effective in combination than as monotherapies in SHR.


Subject(s)
Adrenergic alpha-Antagonists/pharmacology , Adrenergic beta-Antagonists/pharmacology , Angiotensin II Type 1 Receptor Blockers/pharmacology , Atenolol/pharmacology , Cardiomegaly/drug therapy , Doxazosin/pharmacology , Losartan/pharmacology , Angiotensin II/blood , Animals , Blood Pressure/drug effects , Cardiomegaly/diagnostic imaging , Drug Therapy, Combination , Echocardiography , Heart Rate/drug effects , Hypertension/drug therapy , Male , Natriuretic Peptide, Brain/blood , Natriuretic Peptide, Brain/genetics , RNA, Messenger/analysis , Rats , Rats, Inbred SHR
20.
Heart Vessels ; 20(3): 123-5, 2005 May.
Article in English | MEDLINE | ID: mdl-15912310

ABSTRACT

A transient left ventricular apical ballooning (so-called "ampulla" or "Takotsubo-shaped" cardiomyopathy) with type I CD36 deficiency is described in a 71-year-old woman. The patient was referred because of chest pain and worsening of dyspnea. Electrocardiogram showed T-wave inversions on the precordal leads, and acute coronary syndrome was suspected. Left ventricular apical ballooning was observed by echocardiogram and left ventriculography, and coronary arteriography did not reveal any significant stenosis. Left ventricular motion normalized at the follow-up period and there were no increases in specific markers for myocardial damage, such as myocardial band fraction of creatine kinase and troponin T, through out the admission. 123I-metaiodobengylguanidine myocardial single photon emission computed tomography (SPECT) revealed decreased accumulation areas at the apex, while 201Tl SPECT showed normal accumulation. An abnormal metabolism of cardiac free fatty acid was suggested by lack of accumulation of 123I beta-methyliodophenyl pentadecanoic acid (BMIPP) SPECT. No CD36 expression in either platelets or monocytes/macrophages was shown using flow cytometer analysis and type I CD36 deficiency was diagnosed. DNA sequencing showed that the patient had compound heterozygosity of the CD36 gene (a nucleotide change in C478T and an adenine insertion at nucleotide 1159 in exon 10). Although CD36 deficiency is thought to be involved with many cardiovascular disease and metabolic abnormalities, Takotsubo-shaped cardiomyopathy with CD36 deficiency had not been reported. Further studies of Takotsubo-shaped cardiomyopathy and CD36 deficiency may reveal an association between this cardiomyopathy and specific genetic profiles.


Subject(s)
CD36 Antigens/genetics , Cardiomyopathies/diagnosis , Aged , Cardiomyopathies/genetics , Echocardiography , Fatty Acids , Female , Humans , Iodine Radioisotopes , Iodobenzenes , Tomography, Emission-Computed, Single-Photon
SELECTION OF CITATIONS
SEARCH DETAIL
...